Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia

Overview
The researchers designed a split-signaling bispecific CAR to target AML cells while sparing HSCs. CAR T cells were expanded using G-Rex® plates to generate sufficient cell numbers for in vivo xenograft experiments comparing bispecific and monospecific CARs.
What this paper found
A bispecific CD33/CD123 CAR built as an AND logic gate controlled acute myeloid leukemia in mice as well as monospecific CD33 or CD123 CARs, while proving less cytotoxic to CD34+ stem cells. Five de novo anti-CD33 and eight anti-CD123 scFv constructs were first screened against engineered CHO target cells, then 32 double-transduced pairings were compared, and 12 single-construct bispecific CARs were built, of which CAR 1 was selected on cytotoxicity, cytokine release and binding avidity. NSG mice bearing 5 × 10^5 MV411 cells received 1 × 10^6 CAR T cells, with no significant survival difference between CAR groups. In humanized CD34+ mice, body weight and blood counts were unchanged, and colony-forming assays showed more granulocyte macrophage colonies than either monospecific CAR.
Note: Preclinical study. The AND-gate screening relied on engineered CHO target cells, and the authors note that AML cell lines or primary samples carrying different somatic mutations may have added value to the selection of the bispecific CAR.
This meticulously developed CD33/CD123 bispecific CAR has therapeutic potential without on-target off-target toxicity against refractory AML and will be evaluated further in clinical trials. — Justin C. Boucher, Bishwas Shrestha, Paresh Vishwasrao, Mark Leick, Estelle V. Cervantes, Tayyebb Ghafoor, Kayla Reid, Kristen Spitler, Bin Yu, Brian C. Betts, Jose A. Guevara-Patino, Marcela V. Maus, Marco L. Davila, Molecular Therapy - Oncolytics
Study details
- Authors
- Justin C. Boucher, Bishwas Shrestha, Paresh Vishwasrao, Mark Leick, Estelle V. Cervantes, Tayyebb Ghafoor, Kayla Reid, Kristen Spitler, Bin Yu, Brian C. Betts, Jose A. Guevara-Patino, Marcela V. Maus, Marco L. Davila
- Institution
- Department of Blood & Marrow Transplant and Cellular Immunotherapy, Division of Clinical Science, H. Lee Moffitt Cancer Center, Tampa, FL, USA · Department of Radiation Oncology, City of Hope Medical Center, Duarte, CA, USA · Department of Hematology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands · Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, MA, USA · University of South Florida, Tampa, FL, USA · Division of Hematology, Oncology, and Transplant, Department of Medicine, Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA · Department of Immunology, H. Lee Moffitt Cancer Center, Tampa, FL, USA · Department of Medicine and Immunology, Roswell Park Cancer Center, Buffalo, NY, USA
- Journal
- Molecular Therapy - Oncolytics
- Year
- 2023
- Cell type(s)
- CAR T Cells
- Application area
- Hematologic malignancy
- Study phase
- Preclinical
How G-Rex® was used
Healthy donor T cells were activated with CD3/CD28 beads, spin-transduced with gamma retrovirus and, after bead removal at 7 to 8 days of activation, expanded in G-Rex® plates (Wilson Wolf). The G-Rex® expansion step increased T cell yield for the in vivo experiments, in which mice received 1 × 10^6 CAR T cells.
Explore related
Full citation
Boucher JC, Shrestha B, Vishwasrao P, et al. Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia. Mol Ther Oncolytics. 2023;31:100751.
Building a similar workflow?
Talk to a ScaleReady specialist about how the G-Rex® platform can support your program — from process development to clinical-scale manufacturing.